Vyleesi (Bremelanotide) Dosing in Hepatic Impairment

Why Hepatic Impairment Matters for Drug Dosing

Most drugs undergo significant hepatic biotransformation, and liver dysfunction can raise plasma concentrations to toxic levels. The FDA's 2003 guidance for pharmacokinetic studies in hepatic impairment recommends that sponsors evaluate drugs across Child-Pugh categories A, B, and C during development. This guidance applies to all new molecular entities, including peptide therapeutics like bremelanotide [1].

Liver disease alters drug handling through several mechanisms: reduced hepatic blood flow, decreased albumin synthesis (affecting protein binding), impaired phase I and phase II enzymatic capacity, and portal-systemic shunting that bypasses first-pass metabolism [2]. For drugs with high hepatic extraction ratios, even mild cirrhosis can double or triple systemic exposure. Bremelanotide sidesteps many of these concerns because it is a synthetic cyclic peptide that does not rely on cytochrome P450 enzymes for its primary clearance pathway [3].

The Child-Pugh classification system stratifies hepatic impairment by scoring five clinical and laboratory parameters: bilirubin, albumin, INR, ascites, and encephalopathy grade [4]. Class A (5-6 points) indicates compensated cirrhosis. Class B (7-9 points) signals significant compromise. Class C (10-15 points) represents decompensated disease with high mortality risk. Dosing recommendations for bremelanotide map directly to these categories.

Bremelanotide Pharmacokinetics and Hepatic Metabolism

Bremelanotide reaches near-complete bioavailability (approximately 100%) after subcutaneous injection, with peak plasma concentrations (Tmax) occurring at about 1 hour post-dose [3]. The elimination half-life averages 2.7 hours. These parameters matter when assessing liver disease impact because they define the drug's exposure window.

Unlike small-molecule drugs metabolized by CYP3A4 or CYP2D6, bremelanotide is degraded by nonspecific peptidases throughout the body [5]. The Vyleesi prescribing information confirms that the drug undergoes hydrolysis to multiple metabolites, none of which have known pharmacological activity at melanocortin receptors [3]. Renal excretion of intact bremelanotide accounts for approximately 65% of the administered dose, further reducing the liver's role in drug clearance.

Protein binding sits at roughly 21%, meaning that even significant reductions in albumin (common in Child-Pugh B and C patients) would minimally shift the free fraction [3]. A drug with 90% protein binding that drops to 80% effectively doubles its free concentration. A drug at 21% binding that drops to 15% changes free concentration by less than 8%. This pharmacokinetic profile provides the scientific rationale for the FDA's decision not to require dose reductions in mild to moderate liver disease.

FDA Labeling: What the Prescribing Information States

The Vyleesi prescribing information addresses hepatic impairment in Section 8.6 [3]. The label specifies:

• Child-Pugh A (mild): No dosage adjustment necessary.
• Child-Pugh B (moderate): No dosage adjustment necessary.
• Child-Pugh C (severe): Has not been studied.

The FDA's Clinical Pharmacology review (NDA 210557) included a dedicated hepatic impairment study comparing pharmacokinetic parameters in subjects with mild and moderate liver disease against matched healthy controls [6]. In subjects with Child-Pugh A cirrhosis, the area under the curve (AUC) increased by approximately 20% compared to healthy controls. In Child-Pugh B subjects, AUC rose by approximately 50% [3]. Neither of these increases crossed the threshold that FDA reviewers considered clinically meaningful, given the drug's established safety margin at the 1.75 mg dose.

The FDA approval letter dated June 21, 2019 granted approval with the understanding that severe hepatic impairment remained unstudied [7]. No post-marketing requirement was issued to conduct a Child-Pugh C trial, likely because the target population (premenopausal women with HSDD) rarely presents with decompensated cirrhosis.

The RECONNECT Trial: Efficacy Foundation

The approval of bremelanotide rested on the RECONNECT trial, two replicate phase 3 studies (Study 301 and Study 302) enrolling 1,247 premenopausal women with hypoactive sexual desire disorder [8]. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed over 24 weeks.

The co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and the Female Sexual Function Index (FSFI) desire domain score [8]. Bremelanotide produced a statistically significant improvement on both measures. The FSDS-DAO Item 13 score decreased by -0.7 points more than placebo in Study 301 and -0.7 points in Study 302 (P<0.001 for both) [8].

Hepatic impairment was not a pre-specified subgroup in RECONNECT. Patients with significant liver disease (ALT or AST exceeding 2 times the upper limit of normal) were excluded from enrollment [8]. This exclusion criterion is standard in HSDD trials but means that real-world efficacy data in liver disease patients comes only from post-marketing experience and pharmacokinetic bridging studies.

Mechanism of Action: How Bremelanotide Works

Bremelanotide is a synthetic cyclic heptapeptide that acts as a nonselective agonist at melanocortin receptors, particularly the melanocortin-4 receptor (MC4R) in the central nervous system [9]. MC4R activation in hypothalamic and limbic circuits modulates sexual desire through dopaminergic and oxytocinergic signaling pathways. This is distinct from phosphodiesterase-5 inhibitors like sildenafil, which act peripherally on genital blood flow.

The melanocortin system regulates a broad range of physiological processes: energy homeostasis, inflammation, pigmentation, and sexual function [10]. Bremelanotide's affinity for MC4R is approximately 10-fold higher than for MC3R, which may explain its preferential effect on sexual desire versus appetite regulation [9]. Preclinical studies in female rat models demonstrated that intracerebroventricular administration of melanocortin agonists increased solicitation behaviors, an effect blocked by MC4R antagonists [11].

Because MC4R-mediated effects occur centrally and the drug's clearance relies primarily on peptide hydrolysis and renal excretion rather than hepatic CYP metabolism, the mechanism of action itself supports the conclusion that mild to moderate hepatic impairment should not meaningfully alter clinical response [3].

Practical Dosing Guidance for Clinicians

For patients with compensated liver disease (Child-Pugh A or B), prescribe the standard 1.75 mg subcutaneous dose with no modification [3]. The maximum frequency remains one dose per 24 hours, with a monthly cap of 8 doses [3]. Pre-dose blood pressure monitoring is advisable because bremelanotide causes a transient increase in systolic blood pressure (average 6 mmHg) and a decrease in heart rate (average 5 bpm) that peaks about 2-3 hours after injection [12].

For patients with decompensated cirrhosis (Child-Pugh C), the absence of pharmacokinetic data creates a clinical gray zone. The American Association for the Study of Liver Diseases (AASLD) recommends that clinicians weigh the benefit-risk ratio carefully when prescribing any medication lacking severe hepatic impairment data [13]. Given that HSDD is not life-threatening and bremelanotide is an elective, as-needed therapy, most hepatologists would recommend deferring use until liver function improves or stabilizes.

Monitoring recommendations for liver disease patients using bremelanotide:

• Baseline liver function tests (ALT, AST, bilirubin, albumin, INR) before first dose
• Repeat liver panels at 3 months if ongoing use
• Blood pressure assessment before each injection, particularly in patients with portal hypertension
• Documentation of nausea frequency, as nausea (the most common adverse effect at 40% incidence) could worsen nutritional status in cirrhotic patients [3]

Nausea and Other Adverse Effects in Liver Disease Context

Nausea occurred in 40% of bremelanotide-treated patients in the RECONNECT trial versus 1% with placebo [8]. This adverse effect warrants special attention in hepatic impairment for two reasons. First, patients with cirrhosis frequently experience baseline nausea from gastroparesis, portal hypertensive gastropathy, or medication burden [14]. Second, persistent vomiting can precipitate electrolyte imbalances and hepatic encephalopathy in susceptible individuals.

The FDA's review of adverse events noted that nausea was dose-dependent and most pronounced with the first few injections, often attenuating with continued use [6]. In RECONNECT, 13% of subjects experienced nausea severe enough to require antiemetic therapy, and nausea was the leading reason for treatment discontinuation (6.3% of the bremelanotide group) [8].

Flushing occurred in 20% of treated patients, injection site reactions in 13%, and headache in 11% [3]. The transient blood pressure elevation (mean +6 mmHg systolic) is generally inconsequential in healthy premenopausal women but could be clinically relevant in patients with portal hypertension and esophageal varices, where acute pressure changes carry bleeding risk [15].

Hyperpigmentation is a class effect of melanocortin agonists. The prescribing information reports darkening of facial skin, gingiva, and breast tissue in patients using bremelanotide repeatedly [3]. This effect is reversible upon discontinuation but may take weeks to resolve. No evidence suggests that hepatic impairment alters the incidence or severity of melanocortin-mediated pigmentation changes.

Drug Interactions Relevant to Liver Disease Patients

Bremelanotide does not inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations [3]. This is a significant advantage in liver disease patients, who often take multiple medications metabolized through these pathways. Cirrhotic patients on propranolol (CYP2D6/CYP1A2 substrate) for variceal bleeding prophylaxis or spironolactone for ascites management do not need dose modifications when adding bremelanotide [3].

One interaction does require attention. Bremelanotide slows gastric motility, which can reduce the rate of absorption (but not extent) of oral medications [16]. The prescribing information specifically warns about co-administration with orally administered naltrexone, noting that bremelanotide decreased naltrexone Cmax by 44% and delayed its Tmax by 1.5 hours [3]. For liver disease patients taking time-sensitive oral medications (lactulose for encephalopathy, rifaximin for secondary prophylaxis), timing bremelanotide injections to avoid overlapping absorption windows is prudent.

The FDA's clinical pharmacology review also evaluated the interaction between bremelanotide and indomethacin (a CYP2C9 substrate), finding no clinically significant change in indomethacin exposure [6]. This supports the broader conclusion that bremelanotide's drug interaction potential is low regardless of hepatic function status.

Comparing Bremelanotide to Flibanserin in Hepatic Impairment

Flibanserin (Addyi), the other FDA-approved treatment for premenopausal HSDD, presents a starkly different hepatic impairment profile. Flibanserin is extensively metabolized by CYP3A4, CYP2C19, and CYP1A2 [17]. The flibanserin prescribing information contraindicates its use in patients with any degree of hepatic impairment due to a 4.5-fold increase in AUC in Child-Pugh A subjects [17].

This contrast is clinically meaningful. For HSDD patients with liver disease, bremelanotide is the only FDA-approved option available across mild and moderate hepatic impairment [3]. The Endocrine Society's guidelines on female sexual dysfunction acknowledge both pharmacotherapies but do not specifically address hepatic dosing, deferring to product labeling [18].

Prescribers managing HSDD in patients with concurrent liver disease should document the rationale for choosing bremelanotide over flibanserin and note the absence of Child-Pugh C data in the medical record.

Special Populations and Remaining Evidence Gaps

Bremelanotide is approved only for premenopausal women. No data exist for its use in postmenopausal women, men, or transgender patients with HSDD [3]. The hepatic impairment pharmacokinetic study enrolled both male and female subjects, so the pharmacokinetic conclusions apply across sexes even though the clinical indication does not [6].

Patients with non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD) deserve mention. MASLD affects approximately 30% of the global adult population and many of these patients retain normal synthetic function (i.e., they do not meet Child-Pugh criteria for impairment) [19]. For patients with MASLD who have preserved hepatic function, bremelanotide requires no adjustment whatsoever.

Alcohol-related liver disease presents a unique consideration. Acute alcohol ingestion was not studied in combination with bremelanotide, and the prescribing information does not address this scenario [3]. Given that both alcohol and bremelanotide can lower blood pressure transiently and cause nausea, patients should be counseled about the potential for additive effects.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines moderate drinking as up to one standard drink per day for women [20]. Patients with compensated alcohol-related cirrhosis who are abstinent should follow the standard Child-Pugh-based dosing guidance outlined above.

Summary of Dosing Recommendations by Liver Status

| Hepatic Status | Child-Pugh | Bremelanotide Dose | Evidence Level | |---|---|---|---| | Normal function | N/A | 1.75 mg SC PRN | Phase 3 (RECONNECT) | | Mild impairment | A (5-6) | 1.75 mg SC PRN | PK bridging study | | Moderate impairment | B (7-9) | 1.75 mg SC PRN | PK bridging study | | Severe impairment | C (10-15) | Avoid; no data | No study conducted | | MASLD, preserved function | N/A | 1.75 mg SC PRN | Extrapolated |

Patients with fluctuating Child-Pugh scores (for example, those transitioning between B and C during decompensation episodes) should have bremelanotide held during acute deterioration and re-evaluated once clinical stability returns. The 1.75 mg dose should not be split or reduced, as no lower-dose formulation exists and the autoinjector delivers a fixed volume [3].